Sprouts Farmers Market closes $600 million revolving credit facility
In a recent SEC filing, Becton Dickinson & Co (NYSE:BDX), a leading medical technology company, announced the outcomes of its 2025 Annual Meeting held on Monday. Shareholders voted on several key proposals, including the election of directors and the ratification of the company’s independent auditor.
All of the Board of Directors’ nominees were elected to serve one-year terms. The vote results for each nominee ranged from 212,988,078 to 233,523,789 votes in favor, with William M. Brown receiving the highest number of affirmative votes. Votes against the nominees were significantly lower, with the highest opposition at 21,443,621 votes for R. Andrew Eckert. Abstentions and broker non-votes also were recorded, with broker non-votes uniformly at 21,170,297 across all nominees.
Additionally, the appointment of Ernst & Young as the independent registered public accounting firm for the fiscal year 2025 was ratified with a substantial majority. The proposal saw 235,180,130 votes for and 20,249,859 votes against, with 473,629 abstentions.
Furthermore, the compensation of BD’s named executive officers was approved on an advisory, non-binding basis. The proposal received 208,413,830 votes for, 25,696,707 against, and 622,784 abstentions.
The filing also included technical details such as the submission type and public document count, as well as the company’s fiscal year-end and business address. The company’s common stock and various notes are registered on the New York Stock Exchange under different symbols.
This SEC filing provides shareholders and potential investors with essential information regarding the governance of Becton Dickinson and reflects the company’s compliance with regulatory requirements. The press release statement serves as the source of the reported facts.
In other recent news, Becton Dickinson (BD), a global medical technology firm, has announced a quarterly dividend and the authorization of additional share repurchases. The company’s board declared a dividend of $1.04 per common share, and an additional repurchase of up to 10 million shares of common stock. This comes after BD repurchased $750 million of its stock in fiscal 2025.
In terms of earnings, BD reported a 7.4% growth in Q4 revenue and a 5% full-year organic revenue increase in its recent earnings call. The company’s adjusted diluted earnings per share rose by 11.4%, reaching $13.14 for the year. For fiscal year 2025, BD anticipates revenue between $21.9 billion and $22.1 billion, with adjusted diluted EPS guidance of $14.25 to $14.60.
Analysts from Piper Sandler have increased the price target for Becton Dickinson shares to $280 from $275, maintaining an Overweight rating. They have also expressed support for a potential spin-off of the Life Sciences division, suggesting it could provide multiple benefits to shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.